nafamostat has been researched along with Bleeding in 26 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesilate (NFM) is used as an anticoagulant during hemodialysis in patients who have had complications due to hemorrhages." | 8.02 | Possible Role of Electrolytes on the Formation of Precipitates during the Infusion of Nafamostat Mesilate in Hemodialysis. ( Nishi, K; Otagiri, M; Seo, H; Taguchi, K; Tsukigawa, K; Yamasaki, K, 2021) |
| "Nafamostat mesilate, with which we can reduce anticoagulation values of patient to a safe level without losing the ECMO anticoagulation values is expected to be useful as a regional anticoagulant in patients with bleeding complications or a high risk of bleeding during ECMO." | 7.81 | Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. ( Her, C; Jang, HJ; Kim, DK; Min, HK; Park, JH; Park, SH, 2015) |
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 7.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| "107 hemodialysis patients at high risk for intradialytic bleeding due to previous surgery or active bleeding from other sites were treated with nafamostat mesilate (FUT-175; FUT) as hemodialysis anticoagulant for 2 weeks." | 7.68 | Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. ( Akizawa, T; Hirasawa, Y; Kazama, M; Koshikawa, S; Mimura, N; Ota, K, 1993) |
| " However, patients with bleeding risk and/or heparin-related side effects may necessitate alternative strategies: among these, nafamostat mesilate (NM) has been reported." | 5.22 | Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review. ( Astuto, M; Brancati, S; Currò, JM; Dezio, V; La Via, L; Martucci, G; Murabito, P; Pappalardo, F; Sanfilippo, F, 2022) |
| "Nafamostat mesilate (NFM) is used as an anticoagulant during hemodialysis in patients who have had complications due to hemorrhages." | 4.02 | Possible Role of Electrolytes on the Formation of Precipitates during the Infusion of Nafamostat Mesilate in Hemodialysis. ( Nishi, K; Otagiri, M; Seo, H; Taguchi, K; Tsukigawa, K; Yamasaki, K, 2021) |
| "Nafamostat mesilate, with which we can reduce anticoagulation values of patient to a safe level without losing the ECMO anticoagulation values is expected to be useful as a regional anticoagulant in patients with bleeding complications or a high risk of bleeding during ECMO." | 3.81 | Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation. ( Her, C; Jang, HJ; Kim, DK; Min, HK; Park, JH; Park, SH, 2015) |
| " The objectives of this retrospective study were to assess the effect of nafamostat on circuit patency of CRRT and the safety regarding bleeding complications in patients at high risk of bleeding." | 3.78 | The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding. ( Baek, NN; Huh, W; Jang, HR; Kim, DJ; Kim, YG; Lee, JE; Oh, HY, 2012) |
| "Nafamostat mesilate provided sufficient filter survival without causing major bleeding complications despite the prolongation of APTT." | 3.77 | Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study. ( Hosoya, T; Maruyama, Y; Takinami, M; Uchino, S; Yamamoto, H; Yokoyama, K; Yoshida, H, 2011) |
| "107 hemodialysis patients at high risk for intradialytic bleeding due to previous surgery or active bleeding from other sites were treated with nafamostat mesilate (FUT-175; FUT) as hemodialysis anticoagulant for 2 weeks." | 3.68 | Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. ( Akizawa, T; Hirasawa, Y; Kazama, M; Koshikawa, S; Mimura, N; Ota, K, 1993) |
| "Nafamostat has been widely used in acute blood purification at critical care units in Japan." | 2.46 | Anticoagulation in acute blood purification for acute renal failure in critical care. ( Shinoda, T, 2010) |
| "Therefore, hemodialysis using an arteriovenous fistula was induced for renal replacement therapy." | 1.56 | Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A. ( Aomatsu, A; Hirai, K; Hoshino, T; Ishii, H; Ito, K; Kaku, Y; Kaneko, S; Kitano, T; Matsuyama, M; Minato, S; Miyazawa, H; Miyoshi, C; Morino, J; Morishita, Y; Ookawara, S; Shimoyama, H; Shindo, M; Ueda, Y; Yanai, K, 2020) |
| "However, she died of multiple organ failure and systemic cytomegalovirus infection in the chronic stage." | 1.32 | [Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports]. ( Kusaba, T; Matsumuro, A; Nakahara, Y; Nakamura, T; Sawada, S, 2004) |
| "The bleeding was well controlled by FUT administration in 8 of 12 cases." | 1.30 | Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report. ( Fukuta, S; Futamura, M; Kato, J; Nagaya, M; Niimi, N, 1997) |
| "Acute pancreatitis was induced in 19 anesthetized dogs by retrograde injection of bile mixed with trypsin into the pancreatic duct." | 1.28 | Synthetic antiproteases in acute pancreatitis: an experimental study. ( Babicki, A; Basiński, A; Dobosz, M; Juszkiewicz, P; Sledziński, Z; Wajda, Z, 1992) |
| " When a new synthetic antiprotease (nafamstat mesilate) in a dosage of 0." | 1.27 | Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect. ( Koh, I; Nishiwaki, H; Satake, K; Umeyama, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 9 (34.62) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Steinmetzer, T | 1 |
| Pilgram, O | 1 |
| Wenzel, BM | 1 |
| Wiedemeyer, SJA | 1 |
| Miyaji, MJ | 1 |
| Ide, K | 1 |
| Takashima, K | 1 |
| Maeno, M | 1 |
| Krallman, KA | 1 |
| Lazear, D | 1 |
| Goldstein, SL | 1 |
| Sanfilippo, F | 1 |
| Currò, JM | 1 |
| La Via, L | 1 |
| Dezio, V | 1 |
| Martucci, G | 1 |
| Brancati, S | 1 |
| Murabito, P | 1 |
| Pappalardo, F | 1 |
| Astuto, M | 1 |
| Ishii, H | 1 |
| Miyoshi, C | 1 |
| Hirai, K | 1 |
| Morino, J | 1 |
| Minato, S | 1 |
| Kaneko, S | 1 |
| Yanai, K | 1 |
| Matsuyama, M | 1 |
| Kitano, T | 1 |
| Shindo, M | 1 |
| Aomatsu, A | 1 |
| Shimoyama, H | 1 |
| Miyazawa, H | 1 |
| Ito, K | 1 |
| Ueda, Y | 1 |
| Kaku, Y | 1 |
| Hoshino, T | 1 |
| Ookawara, S | 1 |
| Morishita, Y | 1 |
| Yamasaki, K | 1 |
| Nishi, K | 1 |
| Tsukigawa, K | 1 |
| Taguchi, K | 1 |
| Otagiri, M | 1 |
| Seo, H | 1 |
| Miyatake, Y | 2 |
| Makino, S | 2 |
| Kubota, K | 2 |
| Egi, M | 2 |
| Mizobuchi, S | 2 |
| Yamamura, H | 1 |
| Morioka, T | 1 |
| Yamamoto, T | 1 |
| Kaneda, K | 1 |
| Mizobata, Y | 1 |
| Lee, YK | 1 |
| Lee, HW | 1 |
| Choi, KH | 1 |
| Kim, BS | 1 |
| Choi, JY | 1 |
| Kang, YJ | 1 |
| Jang, HM | 1 |
| Jung, HY | 1 |
| Cho, JH | 1 |
| Park, SH | 2 |
| Kim, YL | 1 |
| Kim, CD | 1 |
| Park, JH | 1 |
| Her, C | 1 |
| Min, HK | 1 |
| Kim, DK | 1 |
| Jang, HJ | 1 |
| Kita, H | 1 |
| Shinoda, T | 1 |
| Maruyama, Y | 1 |
| Yoshida, H | 1 |
| Uchino, S | 2 |
| Yokoyama, K | 1 |
| Yamamoto, H | 1 |
| Takinami, M | 1 |
| Hosoya, T | 1 |
| Baek, NN | 1 |
| Jang, HR | 1 |
| Huh, W | 1 |
| Kim, YG | 1 |
| Kim, DJ | 1 |
| Oh, HY | 1 |
| Lee, JE | 1 |
| Kotani, K | 1 |
| Ichiba, S | 1 |
| Andou, M | 1 |
| Sano, Y | 1 |
| Date, H | 1 |
| Tedoriya, T | 1 |
| Goto, K | 1 |
| Shimizu, N | 1 |
| Kusaba, T | 1 |
| Nakahara, Y | 1 |
| Matsumuro, A | 1 |
| Nakamura, T | 1 |
| Sawada, S | 1 |
| Ogata, H | 1 |
| Kinugasa, E | 2 |
| Bellomo, R | 1 |
| Morimatsu, H | 1 |
| Morgera, S | 1 |
| Schetz, M | 1 |
| Tan, I | 1 |
| Bouman, C | 1 |
| Macedo, E | 1 |
| Gibney, N | 1 |
| Tolwani, A | 1 |
| Oudemans-van Straaten, H | 1 |
| Ronco, C | 1 |
| Kellum, JA | 1 |
| Akizawa, T | 2 |
| Koshikawa, S | 2 |
| Ota, K | 1 |
| Kazama, M | 1 |
| Mimura, N | 1 |
| Hirasawa, Y | 1 |
| Nagaya, M | 1 |
| Futamura, M | 1 |
| Kato, J | 1 |
| Niimi, N | 1 |
| Fukuta, S | 1 |
| Morishita, K | 1 |
| Inoue, S | 1 |
| Baba, T | 1 |
| Sakata, J | 1 |
| Kazui, T | 1 |
| Abe, T | 1 |
| Makita, T | 1 |
| Ohtake, Y | 1 |
| Hirasawa, H | 1 |
| Sugai, T | 1 |
| Oda, S | 1 |
| Shiga, H | 1 |
| Matsuda, K | 1 |
| Kitamura, N | 1 |
| Dobosz, M | 1 |
| Sledziński, Z | 1 |
| Babicki, A | 1 |
| Juszkiewicz, P | 1 |
| Basiński, A | 1 |
| Wajda, Z | 1 |
| Masuda, M | 1 |
| Fukamachi, K | 1 |
| Matsuzaki, K | 1 |
| Asou, T | 1 |
| Toshima, Y | 1 |
| Kinoshita, K | 1 |
| Mayumi, H | 1 |
| Tominaga, R | 1 |
| Miyamoto, K | 1 |
| Komori, M | 1 |
| Satake, K | 1 |
| Koh, I | 1 |
| Nishiwaki, H | 1 |
| Umeyama, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT01761994] | Phase 4 | 66 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment[NCT02341885] | 2,000 participants (Actual) | Observational | 2015-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for nafamostat and Bleeding
| Article | Year |
|---|---|
Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review.
Topics: Anticoagulants; Extracorporeal Membrane Oxygenation; Hemorrhage; Heparin; Humans; Retrospective Stud | 2022 |
Anticoagulation in acute blood purification for acute renal failure in critical care.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Critical Care; Guanidines; Hemorrhage; Humans; Ja | 2010 |
[Treatment of uremic patients with high bleeding risk].
Topics: Anticoagulants; Benzamidines; Blood Platelet Disorders; Guanidines; Hemorrhage; Heparin, Low-Molecul | 2004 |
3 trials available for nafamostat and Bleeding
| Article | Year |
|---|---|
Ability of nafamostat mesilate to prolong filter patency during continuous renal replacement therapy in patients at high risk of bleeding: a randomized controlled study.
Topics: Acute Kidney Injury; Adult; Aged; Anticoagulants; Benzamidines; Blood Transfusion; Female; Guanidine | 2014 |
Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Female; Guanidines; Hemorrhage; Humans; Male; Mid | 2015 |
Our distal aortic perfusion system in descending thoracic and thoracoabdominal aortic aneurysm repairs.
Topics: Analysis of Variance; Anticoagulants; Antithrombins; Aortic Aneurysm, Abdominal; Aortic Aneurysm, Th | 1997 |
20 other studies available for nafamostat and Bleeding
| Article | Year |
|---|---|
Fibrinolysis Inhibitors: Potential Drugs for the Treatment and Prevention of Bleeding.
Topics: Animals; Antifibrinolytic Agents; Catalytic Domain; Crystallography, X-Ray; Fibrinolysin; Fibrinolys | 2020 |
Comparison of nafamostat mesilate to citrate anticoagulation in pediatric continuous kidney replacement therapy.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Child; Citrates; Citric Acid; Continuous Renal Re | 2022 |
Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A.
Topics: Aged, 80 and over; Anticoagulants; Arteriovenous Fistula; Benzamidines; Coagulants; Factor VIII; Gua | 2020 |
Possible Role of Electrolytes on the Formation of Precipitates during the Infusion of Nafamostat Mesilate in Hemodialysis.
Topics: Anions; Anticoagulants; Benzamidines; Dialysis Solutions; Electrolytes; Guanidines; Hemorrhage; Huma | 2021 |
Association between Intra-Circuit Activated Clotting Time and Incidence of Bleeding Complications during Continuous Renal Replacement Therapy using Nafamostat Mesilate: a Retrospective Pilot Observational Study.
Topics: Acute Kidney Injury; Adult; Benzamidines; Blood Coagulation; Cohort Studies; Female; Follow-Up Studi | 2017 |
Spontaneous retroperitoneal bleeding: a case series.
Topics: Aged; Anticoagulants; Benzamidines; Embolization, Therapeutic; Female; Guanidines; Hemodiafiltration | 2014 |
Nafamostat mesilate as a regional anticoagulant in patients with bleeding complications during extracorporeal membrane oxygenation.
Topics: Adult; Aged; Anticoagulants; Benzamidines; Extracorporeal Membrane Oxygenation; Female; Guanidines; | 2015 |
Comparison of nafamostat mesilate and unfractionated heparin as anticoagulants during continuous renal replacement therapy.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anticoagulants; Benzamidines; Critical Care; Female; G | 2016 |
Nafamostat mesilate as an anticoagulant during continuous veno-venous hemodialysis: a three-year retrospective cohort study.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Analysis of Variance; Anticoagulants; Benzamidines; Cr | 2011 |
The role of nafamostat mesylate in continuous renal replacement therapy among patients at high risk of bleeding.
Topics: Acute Kidney Injury; Anticoagulants; Benzamidines; Female; Fibrinolysin; Follow-Up Studies; Guanidin | 2012 |
Extracorporeal membrane oxygenation with nafamostat mesilate as an anticoagulant for massive pulmonary hemorrhage after living-donor lobar lung transplantation.
Topics: Acute Disease; Adult; Anticoagulants; Benzamidines; Combined Modality Therapy; Extracorporeal Membra | 2002 |
[Fulminant myocarditis treated with percutaneous cardiopulmonary support and long-term complications: three case reports].
Topics: Acute Disease; Adolescent; Adult; Aged; Anticoagulants; Benzamidines; Cardiopulmonary Bypass; Fatal | 2004 |
Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.
Topics: Acute Kidney Injury; Aged; Anticoagulants; Arrhythmias, Cardiac; Benzamidines; Citrates; Drug Utiliz | 2007 |
Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Topics: Aged; Antithrombins; Benzamidines; Bleeding Time; Blood Cell Count; Female; Guanidines; Hemorrhage; | 1993 |
Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Topics: Anticoagulants; Benzamidines; Extracorporeal Membrane Oxygenation; Guanidines; Hemorrhage; Heparin; | 1997 |
[Treatment of uremic patients at high bleeding risk].
Topics: Benzamidines; Blood Transfusion; Deamino Arginine Vasopressin; Gabexate; Guanidines; Hemorrhage; Hep | 1992 |
Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.
Topics: Anticoagulants; Benzamidines; Guanidines; Hemofiltration; Hemorrhage; Heparin; Heparin, Low-Molecula | 1991 |
Synthetic antiproteases in acute pancreatitis: an experimental study.
Topics: Acute Disease; Animals; Benzamidines; Dogs; Gabexate; Guanidines; Hemodynamics; Hemorrhage; Pancreat | 1992 |
[Clinical assessment of anticoagulation therapy during left ventricular assist with artificial heart: induction with protease inhibitor].
Topics: Aged; Assisted Circulation; Benzamidines; Drug Evaluation; Drug Therapy, Combination; Gabexate; Guan | 1989 |
Toxic products in hemorrhagic ascitic fluid generated during experimental acute hemorrhagic pancreatitis in dogs and a treatment which reduces their effect.
Topics: Acute Disease; Animals; Ascitic Fluid; Benzamidines; Disease Models, Animal; Dogs; Female; Guanidine | 1985 |